Cologuard Available In-Network for Anthem Blue Cro
Post# of 129
Posted On: 06/06/2016 12:00:13 PM
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
06/01/2016
Exact Sciences Completes Contracting with Anthem Commercial and Medicare Advantage Plans in Ind., Ohio, Ky., Mo. and Wis.
MADISON, Wis., June 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
Exact Sciences Corporation (EXACT SCIENCES CORPORATION)
"As Cologuard's in-network status grows in 2016, more people gain access to this innovative screening test," said Kevin Conroy, chairman and CEO of Exact Sciences. "This access gives us more opportunities to find cancer in its earliest, most treatable stages."
With the recent additions, 69 percent of Anthem's 37.6 million members now live in states where Cologuard is contracted as an in-network service.
Anthem is the second-largest commercial health insurer in the United States. Exact Sciences has now entered into contracts with Anthem in eight states, including four where Anthem is the largest private insurer in the state (Va., Ga., Ind. and Wis.). Exact Sciences is seeking to enter into similar agreements with additional Anthem affiliates during 2016.
"The momentum continues to build for Cologuard's commercial coverage and contracting," said Conroy. "Along with more patients gaining in-network access to our test, the execution of our sales strategy and our consumer marketing efforts continue to drive Cologuard awareness among both patients and physicians."
About Cologuard.
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is listed in the screening guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cologuard-available-in-network-for-anthem-blue-cross-and-blue-shield-members-in-five-additional-midwest-states-300277531.html
http://investor.exactsciences.com/investor-re...fault.aspx
06/01/2016
Exact Sciences Completes Contracting with Anthem Commercial and Medicare Advantage Plans in Ind., Ohio, Ky., Mo. and Wis.
MADISON, Wis., June 1, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
Exact Sciences Corporation (EXACT SCIENCES CORPORATION)
"As Cologuard's in-network status grows in 2016, more people gain access to this innovative screening test," said Kevin Conroy, chairman and CEO of Exact Sciences. "This access gives us more opportunities to find cancer in its earliest, most treatable stages."
With the recent additions, 69 percent of Anthem's 37.6 million members now live in states where Cologuard is contracted as an in-network service.
Anthem is the second-largest commercial health insurer in the United States. Exact Sciences has now entered into contracts with Anthem in eight states, including four where Anthem is the largest private insurer in the state (Va., Ga., Ind. and Wis.). Exact Sciences is seeking to enter into similar agreements with additional Anthem affiliates during 2016.
"The momentum continues to build for Cologuard's commercial coverage and contracting," said Conroy. "Along with more patients gaining in-network access to our test, the execution of our sales strategy and our consumer marketing efforts continue to drive Cologuard awareness among both patients and physicians."
About Cologuard.
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is listed in the screening guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cologuard-available-in-network-for-anthem-blue-cross-and-blue-shield-members-in-five-additional-midwest-states-300277531.html
http://investor.exactsciences.com/investor-re...fault.aspx
(1)
(0)